# ImmunityBio

Type: Company (IBRX)

Source: Healthcare Intelligence Brief — https://gethealthbrief.com/entity/immunitybio
Canonical HTML page: https://gethealthbrief.com/entity/immunitybio

## Timeline

- **2026-03-24**: FDA Warning Issued — The FDA flags the podcast statements as misleading and issues an Untitled Letter to ImmunityBio.
- **2026-03-10**: Podcast Appearance — Patrick Soon-Shiong discusses the drug's potential on a high-profile industry podcast.
- **2024-04-22**: Initial FDA Approval — Anktiva (N-803) receives FDA approval for BCG-unresponsive NMIBC.

## Recent coverage (1 stories)

### FDA Issues Warning to ImmunityBio Over Soon-Shiong’s Cancer Drug Claims
2026-03-24 20:18:40 · Sentiment: Negative · Impact: 7/10 · Sources: 2

The FDA has issued a formal warning to ImmunityBio and its founder, Patrick Soon-Shiong, regarding misleading public statements about the company's bladder cancer drug. The regulator cited claims made during a podcast that suggested broader efficacy than currently approved, raising concerns about off-label promotion.
Full story: https://gethealthbrief.com/story/fda-warning-immunitybio-soon-shiong-misleading-claims

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://gethealthbrief.com/guides/methodology for the full editorial methodology.